MSI Methylation Sciences Inc.

MSI Methylation Sciences Inc. is a clinical-stage pharmaceutical company focused on developing new products based on molecules which have clinical proof of concept but which have yet to be exploited in the major pharmaceutical markets.

Strada™, our lead product, is targeting Major Depressive Disorder.

NEWS

January 14, 2020 – MSI Methylation Sciences, Inc. (“MSI”) Update on its Dispute with Quark Venture Inc., now known as 1032951 B.C. Ltd. (“Quark”): Quark’s Court of Appeal Application was Denied, and Quark has Filed a NOI to make a Proposal to its Creditors More

April 15, 2019 – MSI Methylation Sciences, Inc. (MSI) Update on Recent BC Supreme Court Order for Quark Venture Inc. (Quark) to Pay MSI $20 million USD More

October 18, 2018 – MSI Methylation Sciences, Inc. (MSI) provides an update on its corporate activities, including its recent arbitration award of $20 million USD against Quark Venture Inc (Quark). More

January 27, 2016 MSI Methylation Sciences Inc. (MSI) announces results from the Horizon Phase 2 Trial for its Novel Treatment, MSI-195, for Major Depressive Disorder (MDD) More

August 25, 2015 MSI Methylation Sciences Inc. (MSI) Treats the Last Patient in its Horizon Trial and Receives Four Patents to Support its Proprietary Treatment Strada™ for Major Depressive Disorder (MDD) More

May 7, 2015 MSI Methylation Sciences Inc. (MSI) Completes Recruitment of Phase 2 Trial for its Novel Treatment Strada™ for Major Depressive Disorder (MDD)More